Tech Company Financing Transactions
PreciseDx Funding Round
PreciseDx, based in New York, scored $20.7 million from Eventide Asset Management, GenHenn Venture and LabCorp.
Transaction Overview
Company Name
Announced On
8/21/2024
Transaction Type
Venture Equity
Amount
$20,700,000
Round
Series B
Investors
Proceeds Purpose
This capital infusion sets the stage for our next phase of continued in-depth clinical trials to validate PreciseBreast� in a specific clinical setting and market entry point.
Company Information
Company Status
Private & Independent
Industry
Artificial Intelligence
Mailing Address
1111 Amsterdam Stuyvesant Building 8-822
New York, NY 10025
USA
New York, NY 10025
USA
Phone
Website
Email Address
Overview
Our mission is to democratize access to high-quality medical care and information, regardless of the institution or its geographical location. PreciseDx augments current oncology diagnostics and provides an objective review of each patient's risk, eliminating any subjectivity in the review of patient results.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Carlos Cordon-Cardo
Chief Executive Officer
Wayne Brinster
Chief Medical Officer
Michael Donovan
Chief Scientific Officer
Gerardo Fernandez
Chief Technical Officer
Jack Zeineh
VP - Finance
Andrew Borsanyi
Browse more venture capital transactions:
Prev: 8/21/2024: ALLCITY Network venture capital transaction
Next: 8/21/2024: TransBnk venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs